EFFICACY AND SAFETY OF DULOXETINE IN THE TREATMENT OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS

I Putu Eka Widyadharma, Chiquita Putri Vania Rau, Rizaldy Taslim Pinzon, Yudiyanta Y, Agung Wiwiek Indrayani, Thomas Eko Purwata, Boya Nugraha
  MNJ, pp. 48-55  

Abstract


Background: One of the adverse effects of chemotherapy in the neurological field is chemotherapy-induced peripheral neuropathy (CIPN), it was an adverse effect caused by many chemotherapeutic regimens and a major cause of continuous pain in patients who survived cancer. When the symptoms get worse, survivor’s quality of life is declining and they are often having problems with mental health, insomnia, cognitive functioning, fatigue, physical functioning, and pain. So far the choice of therapy for CIPN is still limited. Now, there was no drug approved to treat pain due to CIPN. Duloxetine are a SNRI (serotonin norepinephrine reuptake inhibitor), which it’s useful in CIPN are highly supported by evidence.

Methods: We conducted a systemactic-computer based literature search on January 4, 2019 in PubMed database for article published between 2013 and 2018. We searched for a literature related with used a duloxetine for management of chemotherapy induced peripheral neuropathy.

Results: From the 4 studies that included in this review, the total participants are 478 patients with neuropathic pain and already get a chemotherapy regiment. From the meta-analysis showed one study had no effect, two studies had small effect, and one study had medium effect.

Conclusion: Duloxetine is a great option for the treatment of CIPN in especially reducing neuropathic pain. 

 


Keywords


Pain. Neuropathic pain, chemotherapy induced peripheral neuropathy, cancer, duloxetine.

Full Text:

PDF

References


Farguhar-Smith P, Brown MRD. Persistent pain in cancer survivors: Pathogenesis and treatment options. Pain Clinical Updates XXIV (London, UK); 2016. 1–8

Purwata TE, Sadeli HA, Yudiyanta, Widyadharma IP, Anwar Y, et al. Characteristics of neuropathic pain in Indonesia: A hospital based national clinical survey. Purwata TE, Sadeli HA, Yudiyanta, Widyadharma IP, Anwar Y, et al. Characteristics of neuropathic pain in Indonesia: A hospital based national clinical survey. Neurology Asia 2015; 20(4) : 389 – 394. Available from : https://www.neurology-asia.org/articles/neuroasia-2015-20(4)-389.pdf

Widyadharma, IP. Pain Education: Nyeri Polineuropati Diabetik. Pustaka Bangsa Press. 2017. 101-109.

Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol; 2012. 82(1):51–77. DOI: 10.1016/j.critrevonc.2011.04.012.

Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer; 2012. 118(20):5171–5178.

DOI: 10.1002/cncr.27489

Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity. Cancer; 2012. 119(2):438–444.

DOI: 10.1002/cncr.27732

Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat; 2016. 159(2):327-33.

DOI: 10.1007/s10549-016-3939-0.

Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, et al. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neuro; 2016. 73(7):860-6

DOI: 10.1001/jamaneurol.2016.0383.

Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and non-small cell lung cancer. Chemother Res Pract; 2012. 913848. DOI: 10.1155/2012/913848

Purwata TE, Widyadharma IP. Pregabalin as the Cornerstone of Treating Neuropathic Pain. PKB XXIII. 2015. 9-21

Esin E, Yalcin S. Neuropathic cancer pain: What we are dealing with? How to manage it? OncoTargets and therapy; 2014. 7: 599-618.

DOI: 10.2147/OTT.S60995

Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice AS, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev; 2013. 11:CD010567.

DOI: 10.1002/14651858.CD010567.pub2

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of clinical oncology: official journal of the American Society of Clinical Oncology; 2014. 32: 1941-1967. DOI: 10.1200/JCO.2013.54.0914

Aziz MT, Good BL, Lowe DK. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. The Annals of pharmacotherapy; 2014. 48:626-632. DOI: 10.1177/1060028014525033

Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] [database on the internet]. London, The Cochrane Collaboration. 2011 [cited 2019 March 9]. Available from http://handbook-5-1. cochrane.org/

Denis DJ. Understanding Cohen’s d [database on the internet]. QUANT. 2012. [cited 2019 March 9]. Available from:

http://www.statpt.com/applied_gen/cohen_d.pdf

Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA; 2013. 309:1359–1367. DOI: 10.1001/jama.2013.2813

Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, et al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. International journal of clinical oncology; 2015. 20(5):866-71.

DOI: 10.1007/s10147-015-0810-y

Avan R, Janbabaei G, Hendouei N, Alipour A, Borhani S, Tabrizi N, et al. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: A randomized clinical trial. Journal of Research in Medical Sciences; 2018. 23:52.

DOI: 10.4103/jrms.JRMS_1068_17.

Wang J, Li Q, Xu B, Zhang T, Chen S, Luo Y. Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy. Chin J Cancer Res; 2017. 29(5):411-418. DOI: 10.21147/j.issn.1000-9604.2017.05.05

Smith EML, Pang H, Ye C, Cirrincione C, Fleishman S, Paskett ED, et al. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): A secondary analysis of randomised controlled trial – CALGB/alliance 170601. European Journal of Cancer Care; 2017. 26(2):e12421. DOI: 10.1111/ecc.12421

Farshchian N, Alavi A, Heydarheydari S, Moradian N. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemotherapy and Pharmacology; 2018. 82(5):787-793.

DOI: 10.1007/s00280-018-3664-y.

Otake K, Yoshino K, Ueda Y, Sawada K, Mabuchi S, Kimura T, et al. Usefulness of Duloxetine for Paclitaxel-Induced Peripheral Neuropathy Treatment in Gynecological Cancer Patients. Anticancer Research; 2015. 35: 359-364. Available from : http://ar.iiarjournals.org/content/35/1/359.full.pdf+html

Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, et al. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer; 2012. 20:1491-1497. DOI: 10.1007/s00520-011-1237-2

Kanbayashi Y, Inagaki M, Ueno H, Hosokawa T. Predictors of the usefulness of duloxetine for chemotherapy- induced peripheral neuropathy. Med Oncol; 2017. 34:137. DOI: 10.1007/s12032-017-0995-1

Matsuoka H, Ishiki H, Iwase S, Koyama A, Kawaguchi T, Kizawa Y, et al. Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. BMJ Open; 2017. 7:e017280.

DOI: 10.1136/bmjopen-2017-017280

Okuma K, Shiraishi K, Kanai Y, Nakagawa K. Improvement in quality of life by using duloxetine for chemotherapy-induced peripheral neuropathy (CIPN): a case report. Support Care Cancer; 2016. 24:4483–4485. DOI: 10.1007/s00520-016-3349-1

Pachman DR, Watson JC, Lustberg MB, D Nina, Johnston W, A Chan, et al. Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer; 2014. 22(8):2281-95. DOI: 10.1007/s00520-014-2289-x.

Kane CM, Mulvey MR, Wright S, Craigs C, Wright JM, Bennett MI. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis. Palliat Med; 2018. 32(1):276-286.

DOI: 10.1177/0269216317711826.

Jongen JLM, L Mark, Huijsman, Jessurun J, Ogenio K, Schipper D, et al. The Evidence for Pharmacologic Treatment of Neuropathic Cancer Pain: Beneficial and Adverse Effects. Journal of Pain and Symptom Management; 2013. 46(4):581-590.e1.

DOI: 10.1016/j.jpainsymman.2012.10.230

Kim W, Chung Y, Choi S, Min B, Kim SK. Duloxetine Protects against Oxaliplatin-Induced Neuropathic Pain and Spinal Neuron Hyperexcitability in Rodents. Int. J. Mol. Sci; 2017. 18, 2626. DOI: 10.3390/ijms18122626

Hopkins HL, Duggett NA, Flatters SJL. Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly-used analgesics. Curr Opin Support Palliat Care; 2016. 10(2):119–128.

DOI: 10.1097/SPC.0000000000000204


Refbacks

  • There are currently no refbacks.